The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 265.00
Bid: 260.00
Ask: 270.00
Change: 0.00 (0.00%)
Spread: 10.00 (3.846%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 265.00
ANP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK patent granted for Orego-stim

3 Dec 2021 07:00

RNS Number : 4522U
Anpario PLC
03 December 2021
 

Anpario plc("Anpario" or the "Company")

 

Orego-stim patent granted for reducing antimicrobial resistance

 

Anpario, the independent manufacturer of natural sustainable animal feed additives for health, nutrition, and biosecurity, is pleased to confirm it has successfully been granted a UK patent for market leading phytogenic product Orego-Stim.

 

The patent grant follows a combined and successful research programme with the University of Reading. This research shows that the natural oregano oil composition reduces the proportion of bacteria in the gut that show antimicrobial resistance, when added to the diets of young cattle. This resistance can occur when calves are fed 'waste milk' or colostrum containing antibiotic residues. This 'waste milk', which also contains beneficial microbes for metabolism and immunity, is a major by-product of the dairy industry which cannot be sold for human consumption and so instead, is commonly fed to calves.

 

The inhibition effects of the Orego-Stim on antimicrobial resistance means that those 'highest priority and critically important' antibiotics commonly used in human and animal medicine, such as cephalosporins can be safeguarded for future use. There are other positive aspects to this research which support Anpario's strategy of extending our product technology to maintain animal health through scientific applications.

 

It is hoped that the UK patent will provide a tax benefit to the Group via the UK Patent Box scheme which allows companies to apply a lower rate of corporation tax to profits attributable to qualifying patents. We are currently working with our tax and patent advisors to clarify the scope of qualifying profits and the tax benefit.

 

Further details regarding the research trial can be found on the following link: https://www.anpario.com/media/news/university-trial-shows-anparios-orego-stim-can-help-reduce-antimicrobial-resistance-in-calves/

 

 

 

Enquiries:

Anpario plc

Richard Edwards, CEO

+44(0) 777 6417 129

Marc Wilson, Group Finance Director

+44(0) 1909 537380

Peel Hunt LLP (NOMAD)

+44 (0)20 7418 8900

Adrian Trimmings

Andrew Clark

Will Bell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFSUEEEEFSEDE
Date   Source Headline
21st Mar 202411:37 amRNSDirector/PDMR Shareholding
21st Mar 20247:00 amRNSDirector/PDMR Shareholding
5th Feb 20247:00 amRNSAward of Options and Director/PDMR Shareholding
24th Jan 20247:00 amRNSFull year trading statement
17th Jan 20247:00 amRNSBlock listing Interim Review
5th Oct 20239:23 amRNSDirector Disclosure
13th Sep 20237:00 amRNSHalf-year Report
25th Aug 20235:10 pmRNSBlock listing Interim Review
1st Aug 20237:00 amRNSDirectorate Change
10th Jul 20232:14 pmRNSHolding(s) in Company
7th Jul 20232:34 pmRNSHolding(s) in Company
29th Jun 20233:57 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
23rd Jun 20237:00 amRNSResult of Tender Offer
19th Jun 20232:48 pmRNSGM Statement
15th Jun 20237:00 amRNSShareholder Tour
7th Jun 20234:09 pmRNSReplacement - Tender Offer
6th Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
2nd Jun 20237:00 amRNSTender Offer
23rd May 20237:00 amRNSChange of Adviser
19th May 20234:40 pmRNSDirector Disclosures
19th May 20233:35 pmRNSTotal Voting Rights
5th May 20237:00 amRNSDirectorate Change
21st Apr 20237:00 amRNSAnpario receives King’s Award for Enterprise
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
31st Mar 20231:13 pmRNSHolding(s) in Company
28th Mar 20237:00 amRNSDirector/PDMR Shareholding
22nd Mar 20237:00 amRNSFinal Results
3rd Feb 20237:00 amRNSDirector/PDMR Shareholding
24th Jan 202312:56 pmRNSBlock listing Interim Review
9th Jan 20237:00 amRNSFull Year Trading Statement
16th Dec 20227:00 amRNSAnpario receives ISO 14001 Certification
4th Nov 202212:52 pmRNSTotal Voting Rights
19th Oct 20227:00 amRNSDirector/PDMR Shareholding - Replacement
18th Oct 20227:00 amRNSDirector/PDMR Shareholding
6th Oct 20227:00 amRNSESG Initiatives
3rd Oct 20222:32 pmRNSDirector/PDMR Shareholding
14th Sep 20227:00 amRNSHalf-year Report
5th Sep 202212:38 pmRNSTotal Voting Rights
5th Aug 20222:00 pmRNSBob The Pigeon Back Home in Gateshead, Pet!
20th Jul 20221:02 pmRNSBlock listing Interim Review
7th Jul 20222:59 pmRNSHolding(s) in Company
22nd Jun 202211:24 amRNSAGM Statement
16th Jun 20226:00 pmRNSResult of AGM
16th Jun 20227:00 amRNSAGM Statement
27th May 202212:56 pmRNSHolding(s) in Company
24th May 20221:10 pmRNSHolding(s) in Company
11th May 20227:00 amRNSNotice of AGM
10th May 20223:55 pmRNSHolding(s) in Company
5th May 20223:18 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.